Lung Cancer Treatment Trial
Phase 2
99
about 9.6 years
18+
38 sites in CA, CO, CT +15
About this study
This trial is testing different treatments for lung cancer. It includes drugs, surgery (resection), and radiation therapy (SBRT). The goal is to find the best treatment option based on specific characteristics of each patient's tumor.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Alectinib
- 2.Take Atezolizumab
- 3.Take Chemotherapy
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
alectinib, atezolizumab, cobimetinib, entrectinib, pralsetinib, vemurafenib
oral (Oral Capsule), injection (Injection), oral (Oral Tablet), oral
Primary: KRAS Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs), KRAS Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related Adverse Events as Reported by the Investigator
Secondary: Circulating tumor DNA (ctDNA) Clearance Rate, Disease-free Survival (DFS), Event-free Survival (EFS), Investigator-assessed Response Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Overall Survival (OS), Percentage of Participants With Adverse Events (AEs)
surgery
Oncology